Clinical Trials Logo

Clinical Trial Summary

Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+ precursors, is associated with improvement in cardiac function. This Study will randomize participants with systolic HF (ejection fraction ≤40%) to treatment with the NAD precursor, nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg twice daily, to determine the safety and tolerability of NR in participants with systolic HF.


Clinical Trial Description

Aim 1: Determine the safety and tolerability of NR in patients with clinically stable, systolic heart failure (LVEF <40%). To accomplish this Aim:

A) a total of 30 participants with clinically stable, systolic heart failure (LVEF <40%) will undergo 2:1 randomization to NR 250mg PO twice daily or matching placebo B) NR (or matching placebo), will be increased weekly by 250mg/dose (500mg/day) to a final dose of 1000mg PO twice daily. Clinic visits with labs bi-weekly during dose escalation will assess HF symptoms and monitor labs [B-type natriuretic peptide (BNP), complete blood count (CBC), glycosylated hemoglobin, alanine aminotransferase (ALT), creatine kinase (CK), insulin/glucose, uric acid, electrolytes, blood urea nitrogen (BUN) and creatinine (Cr).

C) to ensure intermediate-term safety and tolerability, participants will continue on their maximum tolerated dose (of NR or placebo) through Study Week 12

Aim 2: Determine whether, at the doses employed, NR and NAD are detectable in whole blood.

Aim 3 (Exploratory): Assess the range of potential effect sizes of NR on HF surrogate endpoints using:

A) Six-minute walk tests (6MWTs) at each visit (including Screening) to assess functional capacity B) Echocardiography at Baseline and Week 12 to assess LV systolic function (by real-time, 3D echocardiography) and diastolic function (by integrated Doppler and tissue Doppler imaging) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03423342
Study type Interventional
Source University of Washington
Contact Kevin D O'Brien, MD
Phone 206 685-3930
Email cardiac@uw.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date May 19, 2016
Completion date June 30, 2018

See also
  Status Clinical Trial Phase
Withdrawn NCT03227393 - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG N/A
Suspended NCT02997670 - Quartet Lead With Defibrillator Multisite Algorithmic Cardiac Resynchronisation Therapy Optimisation N/A
Recruiting NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Active, not recruiting NCT02334891 - Kyoto Congestive Heart Failure Study N/A
Recruiting NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A
Recruiting NCT02960685 - Telesonography for Visually Estimating Ejection Fraction N/A
Recruiting NCT02973594 - Pulse Reduction On Beta-blocker and Ivabradine Therapy Phase 4
Recruiting NCT02579200 - Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Phase 4
Active, not recruiting NCT01553045 - Reasons for Variations in Health Related Quality of Life and Symptom Burden in Patients With Atrial Fibrillation N/A
Completed NCT02946476 - Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients N/A
Recruiting NCT03220659 - Optimising Pacemaker Therapy Using Multi-point Pacing (the OPT-MPP Study) N/A
Recruiting NCT03089502 - Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity N/A
Recruiting NCT03183011 - Cardiac Magnetic Resonance Imaging After Cardiac Resynchronization Therapy N/A
Not yet recruiting NCT03374891 - A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators N/A
Recruiting NCT03387163 - Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Completed NCT02401126 - Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure Phase 4
Recruiting NCT02099903 - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease N/A
Not yet recruiting NCT02026505 - Evaluation of Cardiotoxic Effects of Bortezomib N/A
Completed NCT03073356 - Ketones in Heart Failure - Effects on Cardiac Efficiency Phase 2